

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – January 9, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. December 12, 2012 DUR Minutes – Vote
 - B. December 13, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity for December 2012
 - B. Pharmacy Help Desk Activity for December 2012
 - C. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Linzess™ and Update Amitiza® Criteria – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

6. **60 Day Notice to Prior Authorize Chronic Obstructive Pulmonary Disease Medications – See Appendix D.**
 - A. Utilization Review
 - B. Cost Comparison
 - C. Economic Impact
 - D. Market Analysis
 - E. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Antihyperlipidemics and 30 Day Notice to Prior Authorize Vascepa™ and Juxtapid™ – See Appendix E.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. Vascepa™ and Juxtapid™ Product Summaries
 - F. COP Recommendations
 - G. Utilization Details
 - H. Vascepa™ and Juxtapid™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Osteoporosis Medications and 30 Day Notice to Prior Authorize Binosto™ See Appendix F.**
- A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Binosto™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Xeljanz® – See Appendix G.**
- A. Summary
 - B. Mechanism of Action
 - C. Efficacy
 - D. Safety
 - E. Cost
 - F. COP Recommendations
 - G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
11. **Future Business**
- A. DUR of Oral Corticosteroids
 - B. Annual Reviews
 - C. New Product Reviews
12. **Adjournment**